Consortium Psychiatricum
2024. Том 5. № 3. С. 31–41
doi:10.17816/CP15525
ISSN: 2712-7672 / 2713-2919 (online)
Биологические методы диагностики депрессивных симптомов при шизофрении: нарративный обзор литературы
Аннотация
ВВЕДЕНИЕ: Депрессивная симптоматика при шизофрении приводит к более частым обострениям основного заболевания, ухудшению прогноза и повышению риска суицида. Перед клиницистами до сих пор стоит вопрос, связанный с трудностями диагностики этого расстройства.
ЦЕЛЬ: Произвести обзор литературы, направленный на поиск информации о биомаркерах депрессивных проявлений при шизофрении.
МЕТОДЫ: Поиск данных литературы осуществляли с применением следующих электронных сервисов для поиска публикаций (также указано общее число источников, обнаруженных по искомой теме): ACCESSSS (n=150), Cochrane Library (n=48), PubMed (n=623), eLIBRARY (n=216), Google Scholar (n=367). В итоговое обсуждение было включено 67 публикаций, соответствующих цели работы и опубликованных не ранее 01.01.2018 и не позднее 31.12.2023.
РЕЗУЛЬТАТЫ: При суммировании разрозненных данных предположено, что плазменные показатели (концентрация С-реактивного белка, метаболические, гормональные, ферментативные показатели, значения нейротрофических факторов) слабоспецифичны для диагностики депрессивных симптомов при шизофрении. С помощью методов нейровизуализации установлено, что уменьшение объема серого вещества в теменной, лобной и височной доле (особенно в зонах Брока и Вернике), а также в префронтальной коре — в медиальной части правой верхней лобной, медиальной орбитофронтальной, верхней и средней фронтальных извилины — связано с депрессивными проявлениями. Предполагается связь между генами SIRT1, OXT, CDKAL1 и APOE в возникновении депрессивных симптомов у пациентов с шизофренией.
ЗАКЛЮЧЕНИЕ: Понимание и выявление депрессивных симптомов при шизофрении позволит улучшить качество помощи, получаемой пациентами с этим расстройством.
Общая информация
Ключевые слова: симптомы депрессии, шизофрения, нейробиология
Рубрика издания: Обзоры
Тип материала: научная статья
DOI: https://doi.org/10.17816/CP15525
Получена: 26.03.2024
Принята в печать:
Для цитаты: Султанова Р.И., Гашкаримов В.Р., Ефремов И.С., Асадуллин А.Р. Биологические методы диагностики депрессивных симптомов при шизофрении: нарративный обзор литературы // Consortium Psychiatricum. 2024. Том 5. № 3. С. 31–41. DOI: 10.17816/CP15525
Литература
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington: American Psychiatric Publishing; 2013. 947 p. doi: 10.1176/appi.books.9780890425596
- Bleuler E. Dementia praecox, oder Gruppe der Schizophrenien. Leipzig und Vienna: F. Deuticke; 1911. 420 S.
- The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic criteria for research ICD-10. Geneva: World Health Organization; 1993. 248 p.
- Upthegrove R, Marwaha S, Birchwood M. Depression and schizophrenia: cause, consequence, or trans-diagnostic issue? Schizophr Bull. 2017;43(2):240–244. doi: 10.1093/schbul/sbw097
- Mosolov SN. Diagnosis and treatment depression in schizophrenia. Consort Psychiatr. 2020;1(2):29–42. doi: 10.17816/CP29-42
- Bassett AS, Bury A, Honer WG. Testing Liddle’s three-syndrome model in families with schizophrenia. Schizophr Res. 1994;12(3):213–221. doi: 10.1016/0920-9964(94)90031-0
- Mosolov SN, Malyutin AV, Pikalov AA. [Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(12):29–37. Russian. doi: 10.17116/jnevro201911912129
- ICD-11 for mortality and morbidity statistics [Internet]. 2018 [cited 2022 Jul 25]. Available from: https://icd.who.int/browse/2018/mms/en
- Pavlichenko AV, Kulygina MA, Kostyuk GP. [Schizophrenia and other psychotic disorders in ICD-11 and DSM-5: evolution of the concepts and current status]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2020;120(6 Iss. 2):5–12. Russian.
- Liu J, Chan TCT, Chong SA, et al. Impact of emotion dysregulation and cognitive insight on psychotic and depressive symptoms during the early course of schizophrenia spectrum disorders. Early Interv Psychiatry. 2020;14(6):691–697. doi: 10.1111/eip.12895
- Kim M, Lee Y, Kang H. Effects of Exercise on Positive Symptoms, Negative Symptoms, and Depression in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2023;20(4):3719. doi: 10.3390/ijerph20043719
- Novitskiy MA, Shnayder NA, Bugay VA, et al. [Use of parametric methods and questionnaires for the study of depressive and anxiety disorders in schizophrenia]. Doctor.Ru. 2021;20(5):55–61. Russian. doi: 10.31550/1727-2378-2021-20-5-55-61
- Siris SG, Braga RJ. Depression in schizophrenia [Internet]. 2023 [cited 2024 Jul 12]. Available from: https://medilib.ir/uptodate/show/14791
- Mazoм GE, Ganzenko MA, Rukavishnikov GV, et al. [Depression in schizophrenia: approaches to therapy: methodological recommendations]. Saint Petersburg: V. M. Bekhterev National Medical Research Center of Psychiatry and Neurology; 2020. 22 p. Russian.
- Andira S, Nuralita NS. [Influence of Sexual Differences on Depressive Symptom of Schizophrenia Patients in Rumah Sakit Jiwa Prof. Dr. M. Ildrem Medan North Sumatra 2017]. Buletin Farmatera. 2018;3(2):97–108. Indonesian.
- Häfner H. From onset and prodromal stage to a life-long course of schizophrenia and its symptom dimensions: how sex, age, and other risk factors influence incidence and course of illness. Psychiatry J. 2019;9804836. doi: 10.1155/2019/9804836
- Wang TT, Beckstead JW, Yang CY. Social interaction skills and depressive symptoms in people diagnosed with schizophrenia: The mediating role of auditory hallucinations. Int J Ment Health Nurs. 2019;28(6):1318–1327. doi: 10.1111/inm.12643
- McGinty J, Haque MS, Upthegrove R. Depression during first episode psychosis and subsequent suicide risk: a systematic review and meta-analysis. Schizophr Res. 2018;195:58–66. doi: 10.1016/j.schres.2017.09.040
- Vauth R, Carpiniello B, Turczyński J, et al. Relationship between clinical outcomes measures and personal and social performance functioning in a prospective, interventional study in schizophrenia. Int J Methods Psychiatr Res. 2021;30(2):e1855. doi: 10.1002/mpr.1855
- Rostami R, Kazemi R, Khodaie-Ardakani MR, et al. The Persian version of the Calgary depression scale for schizophrenia (CDSS-P). Asian J Psychiatry. 2019;45:44–49. doi: 10.1016/j.ajp.2019.08.017
- Hettige NC, Bani-Fatemi A, Sakinofsky I, et al. A biopsychosocial evaluation of the risk for suicide in schizophrenia. CNS Spectr. 2018;23(4):253–263. doi: 10.1017/S1092852917000128
- Sher L, Kahn RS. Suicide in schizophrenia: an educational overview. Medicina (Kaunas). 2019;55(7):361. doi: 10.3390/medicina55070361
- Simon GE, Stewart C, Yarborough BJ, et al. Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. JAMA Psychiatry. 2018;75(3):254–260. doi: 10.1001/jamapsychiatry.2017.4437
- Schwarz E, Guest P, Rahmoune H et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 17. (2012);494–502. doi: 10.1038/mp.2011.42
- Stoeber G, Opler LA, Reis HJ, Schmitt A, Convit A, Lawrie SM, et al. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry. 2009;10(2):127-55. doi: 10.1080/15622970802573031
- DiCenso A, Bayley L, Haynes RB. Accessing pre-appraised evidence: fine-tuning the 5S model into a 6S model. Evid Based Nurs. 2009;12(4):99–101. doi: 10.1136/ebn.12.4.99
- Faugere M, Micoulaud-Franchi JA, Faget-Agius C, et al. High C-reactive protein levels are associated with depressive symptoms in schizophrenia. J Affect Disord. 2018;225:671–675. doi: 10.1016/j.jad.2017.08.071
- Fang X, Chen L, Wang D, et al. Metabolic profiling identifies TC and LDL as potential serum biomarkers for depressive symptoms in schizophrenia. Psychiatry Res. 2019;281:112522. doi: 10.1016/j.psychres.2019.112522
- Xu J, Jiao Y, Xing M, et al. Increased plasma leptin as a novel predictor for psychopathological depressive symptoms in chronic schizophrenia. Gen Psychiatr. 2018;31(3):e100018. doi: 10.1136/gpsych-2018-100018
- Kumar P, Kraal AZ, Prawdzik AM, et al. Dietary glutamic acid, obesity, and depressive symptoms in patients with schizophrenia. Front Psychiatry, 2021;11:620097. doi: 10.3389/fpsyt.2020.620097
- Miller BJ, McEvoy JP, McCall WV, et al. Lower adiponectin levels as a predictor of depressive symptoms in African-American males with schizophrenia. Shizophr Res. 2022;250:134–136. doi: 10.1016/j.schres.2022.11.01
- Lang XE, Zhang H, Wang N, et al. Elevated activity of plasma superoxide dismutase in never-treated first-episode schizophrenia patients: Associated with depressive symptoms. Schizophr Res. 2020;222:291–296. doi: 10.1016/j.schres.2020.05.032
- Bigseth TT, Engh JA, Egeland J, et al. Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms. BMC Psychiatry. 2021;21(1):527. doi: 10.1186/s12888-021-03522-6
- Peng S, Li W, Lv L, et al. BDNF as a biomarker in diagnosis and evaluation of treatment for schizophrenia and depression. Discov Med. 2018;26(143):127–136.
- Manchia M, Isayeva U, Collu R, et al. Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders. Brain Sci. 2022;12(12):1666. doi: 10.3390/brainsci12121666
- Wu Y, Du X, Yang R, et al. Association Between Depressive Symptoms and Serum Brain-Derived Neurotrophic Factor Levels in Patients with First-Episode and Drug-Naïve Schizophrenia. Front Psychiatry. 2022;13:911384. doi: 10.3389/fpsyt.2022.911384
- Han D, Sun D, Xiu M, et al. Association between the improvement in depressive symptoms and serum BDNF levels in drug-naive first episode patients with schizophrenia: a longitudinal follow-up. Psychoneuroendocrinology. 20214; 133:105392. doi: 10.1016/j.psyneuen.2021.105392
- Arabska J, Łucka A, Strzelecki D, et al. In schizophrenia serum level of neurotrophin-3 (NT-3) is increased only if depressive symptoms are present. Neurosci Lett. 2018;684:152–155. doi: 10.1016/j.neulet.2018.08.005
- van Erp TGM, Walton E, Hibar DP, et al. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium. Biol Psychiatry. 2018;84(9):644–654. doi: 10.1016/j.biopsych.2018.04.023
- Gray JP, Müller VI, Eickhoff SB, et al. Multimodal abnormalities of brain structure and function in major depressive disorder: a meta-analysis of neuroimaging studies. Am J Psychiatry. 2020;177(5):422–434. doi: 10.1176/appi.ajp.2019.19050560
- Siddi S, Nuñez C, Senior C, et al. Depression, auditory-verbal hallucinations, and delusions in patients with schizophrenia: Different patterns of association with prefrontal gray and white matter volume. Psychiatry Res Neuroimaging. 2019;283:55–63. doi: 10.1016/j.pscychresns.2018.12.001
- Wei GX, Ge L, Chen LZ, et al. Structural abnormalities of cingulate cortex in patients with first-episode drug-naïve schizophrenia comorbid with depressive symptoms. Hum Brain Mapp. 2021;42(6):1617–1625. doi: 10.1002/hbm.25315
- Zhuo C, Fang T, Chen C, et al. Brain imaging features in schizophrenia with co-occurring auditory verbal hallucinations and depressive symptoms – Implication for novel therapeutic strategies to alleviate the reciprocal deterioration. Brain Behav. 2021;11(2):e01991. doi: 10.1002/brb3.1991
- Ji F, Chen C, Chen M, et al. Brain impairment in chronic schizophrenia patients with depressive symptoms differs from brain impairment in chronic depression patients with psychotic symptoms. Chin Med J (Engl). 2018;131(5):620–621. doi: 10.4103/0366-6999.226060
- Shor O, Yaniv-Rosenfeld A, Valevski A, et al. EEG-based spatio-temporal relation signatures for the diagnosis of depression and schizophrenia. Sci Rep. 2023;13(1):776. doi: 10.1038/s41598-023-28009-0
- Liu J, Zheng L, Fang T, et al. Exploration of the cortical pathophysiology underlying visual disturbances in schizophrenia comorbid with depressive disorder — An evidence from mouse model. Brain Behav. 2021;11(5):e02113. doi: 10.1002/brb3.2113
- Zhou C, Kong D, Zhu X, et al. Rethinking schizophrenia and depression comorbidity as one psychiatric disorder entity: evidence from mouse model. Front Neurosci. 2020;14:115. doi: 10.3389/fnins.2020.00115
- Wan L, Li Y, Zhang Z, et al. Methylenetetrahydrofolate reductase and psychiatric diseases. Transl Psychiatry. 2018;8(1):242. doi: 10.1038/s41398-018-0276-6
- Zhang Y, Zhao J, Wang W, et al. Homocysteine, but not MTHFR gene polymorphism, influences depressive symptoms in patients with schizophrenia. J Affect Disord. 2020;272:24–27. doi: 10.1016/j.jad.2020.03.121
- Fang X, Chen Y, Wang Y, et al. Depressive symptoms in schizophrenia patients: a possible relationship between SIRT1 and BDNF. Prog Neuropsychopharmacol Biol Psychiatry. 2019;95:109673. doi: 10.1016/j.pnpbp.2019.109673
- Shkundin A, Halaris A. Associations of BDNF/BDNF-AS SNPs with depression, schizophrenia, and bipolar disorder. J Pers Med. 2023;13(9):1395. doi: 10.3390/jpm13091395
- Lu G, Li J, Zhang H, et al. Role and possible mechanisms of Sirt1 in depression. Oxid Med Cell Longev. 2018;2018:8596903. doi: 10.1155/2018/8596903
- Wang D, Tang W, Zhao J, et al. A comprehensive analysis of the effect of SIRT1 variation on the risk of schizophrenia and depressive symptoms. Front Genet. 2020;11:832. doi: 10.3389/fgene.2020.00832
- Broniarczyk-Czarniak M, Szemraj J, Śmigielski J, et al. The role of OXT, OXTR, AVP, and AVPR1a gene expression in the course of schizophrenia. Curr Issues Mol Biol. 2022;44(1):336–349. doi: 10.3390/cimb44010025
- Hughes ZH, Hughes LM, Khan SS. Genetic contributions to risk of adverse pregnancy outcomes. Curr Cardiovasc Risk Rep. 2023;17(11):185–193. doi: 10.1007/s12170-023-00729-y
- Li W. Association of APOE E2 and low-density lipoprotein with depressive symptoms in Chinese senile schizophrenia inpatients: A cross-sectional study. Schizophr Res Cogn. 2020;23:100193. doi: 10.1016/j.scog.2020.100193
- Krynicki CR, Upthegrove R, Deakin JFW, et al. The relationship between negative symptoms and depression in schizophrenia: A systematic review. Acta Psychiatr Scand. 2018;137(5):380–390. doi: 10.1111/acps.12873
- Lalousis PA, Schmaal L, Wood SJ, et al. Neurobiologically based stratification of recent-onset depression and psychosis: identification of two distinct transdiagnostic phenotypes. Biol Psychiatry. 2022;92(7):552–562. doi: 10.1016/j.biopsych.2022.03.021
- Ruderfer DM, Ripke S, McQuillin A, et al. Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. Cell. 2018;173(7):1705–1715.e16. doi: 10.1016/j.cell.2018.05.046
- van Rooijen G, Vermeulen JM, Ruhé HG, et al. Treating depressive episodes or symptoms in patients with schizophrenia. CNS Spectr. 2019;24(2):239–248. doi: 10.1017/S1092852917000554
- Naguy A. Depression in schizophrenia – A good or bad omen? Asia Pac Psychiatry. 2018;10(2):e12312. doi: 10.1111/appy.12312
- Mosolov SN, Tsukarzi EE. Psychopharmacotherapy of schizophrenia. In: Psihiatriya: nacional’noe rukovodstvo. Moscow: GEOTAR-Media; 2021. p. 252–278. Russian.
- Maslenikov NE, Tsukarzi EE, Mosolov SN. [Algorithm of biological treatment for depression in schizophrenia]. Sovremennaja terapija psihicheskih rasstrojstv. 2019;(1):31–40. Russian. doi: 10.21265/PSYPH.2019.34.92.005
- Edwards CJ, Garety P, Hardy A. The relationship between depressive symptoms and negative symptoms in people with non-affective psychosis: a meta-analysis. Psychol Med. 2019;49(15):2486–2498. doi: 10.1017/S0033291719002381
- Guessoum SB, Le Strat Y, Dubertret C, et al. A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2020;99:109862. doi: 10.1016/j.pnpbp.2020.109862
- Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519–534. doi: 10.2147/NDT.S225643
- Demyttenaere K, Anthonis E, Correll CU. Depressive symptoms and PANSS symptom dimensions in patients with predominant negative symptom schizophrenia: a network analysis. Front Psychiatry. 2022;13:795866. doi: 10.3389/fpsyt.2022.795866
Информация об авторах
Метрики
Просмотров
Всего: 28
В прошлом месяце: 22
В текущем месяце: 6
Скачиваний
Всего: 6
В прошлом месяце: 6
В текущем месяце: 0